Recent Updates — INM

InMed Pharmaceuticals Inc. received a notice from Nasdaq on September 16, 2026, indicating non-compliance with Listing Rule 5550(b)(1) due to shareholders' equity of $1,075,007 falling below the $2,500,000 minimum requirement. The decline in equity stems from transaction expenses related to its merger agreement with Mentari Therapeutics, wind-down costs for subsidiary BayMedica, and operating losses. InMed has 45 days until November 2, 2026, to submit a compliance plan and may receive an extension of up to 180 days. The company expects the merger, anticipated to close in Q4 2026 with approximately $490 million in aggregate gross proceeds from Mentari's pre-closing financing, will restore compliance. InMed Pharmaceuticals Inc. is a pharmaceutical company developing proprietary small molecule drug candidates for diseases with high unmet medical needs.

Mentari Therapeutics, Inc. announced a $200 million private placement of common stock and pre-funded warrants to healthcare investors including Fairmount, Venrock, and Blackstone. This additional financing, occurring concurrently with a previously announced $290 million private placement, is intended to most likely extend Mentari's cash runway into 2029 to support clinical development of its migraine prevention pipeline. InMed Pharmaceuticals Inc. is a biotechnology company that develops therapies for migraine prevention.

InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, Inc. to clarify transaction sequencing, including a name change to Mentari Therapeutics, Inc. and redomestication to Nevada. The amendment introduces a Company PIPE Amendment to facilitate potential pre-closing private placement financing and clarifies tax treatment as an integrated reorganization. InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing medicinal plant-derived cannabinoid-based therapeutics.

InMed Pharmaceuticals Inc. received notice from Nasdaq on June 3, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company had previously been notified of non-compliance on March 27, 2026, after its shares closed below $1.00 for 30 consecutive trading days. InMed Pharmaceuticals is a pharmaceutical company that develops and commercializes medical treatments.